Guggenheim reiterated their hold rating on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Friday morning.
RVNC has been the topic of a number of other reports. Piper Jaffray set a $48.00 target price on Revance Therapeutics and gave the stock a buy rating in a research note on Thursday, March 1st. ValuEngine upgraded Revance Therapeutics from a sell rating to a hold rating in a research note on Friday, February 2nd. Cantor Fitzgerald reiterated a buy rating and set a $50.00 target price on shares of Revance Therapeutics in a research note on Monday, April 2nd. Zacks Investment Research upgraded Revance Therapeutics from a sell rating to a hold rating in a research note on Tuesday, March 6th. Finally, Cowen set a $55.00 target price on Revance Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 17th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $44.67.
Shares of NASDAQ:RVNC opened at $30.60 on Friday. Revance Therapeutics has a 1-year low of $18.42 and a 1-year high of $37.45. The firm has a market cap of $1,124.03, a price-to-earnings ratio of -7.63 and a beta of 1.33.
Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.15). Revance Therapeutics had a negative net margin of 46,025.57% and a negative return on equity of 64.40%. The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. During the same quarter last year, the business posted ($0.95) earnings per share. Revance Therapeutics’s revenue was down 50.7% on a year-over-year basis. equities research analysts anticipate that Revance Therapeutics will post -3.56 earnings per share for the current year.
In related news, CEO L Daniel Browne sold 6,452 shares of the business’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $31.64, for a total value of $204,141.28. Following the sale, the chief executive officer now directly owns 130,208 shares in the company, valued at approximately $4,119,781.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Lauren P. Silvernail sold 3,431 shares of the business’s stock in a transaction dated Thursday, March 22nd. The shares were sold at an average price of $30.85, for a total value of $105,846.35. Following the completion of the sale, the chief financial officer now owns 68,371 shares in the company, valued at $2,109,245.35. The disclosure for this sale can be found here. Insiders sold a total of 98,366 shares of company stock worth $3,182,947 over the last 90 days. 18.86% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. Franklin Resources Inc. raised its stake in Revance Therapeutics by 3.2% in the 4th quarter. Franklin Resources Inc. now owns 3,394,202 shares of the biopharmaceutical company’s stock valued at $121,343,000 after acquiring an additional 105,424 shares during the period. Bank of New York Mellon Corp raised its stake in Revance Therapeutics by 6.7% in the 4th quarter. Bank of New York Mellon Corp now owns 2,144,669 shares of the biopharmaceutical company’s stock valued at $76,672,000 after acquiring an additional 135,356 shares during the period. Alliancebernstein L.P. raised its stake in Revance Therapeutics by 4,063.7% in the 4th quarter. Alliancebernstein L.P. now owns 907,695 shares of the biopharmaceutical company’s stock valued at $32,450,000 after acquiring an additional 885,895 shares during the period. Jennison Associates LLC raised its stake in Revance Therapeutics by 127.1% in the 4th quarter. Jennison Associates LLC now owns 857,536 shares of the biopharmaceutical company’s stock valued at $30,657,000 after acquiring an additional 480,008 shares during the period. Finally, Perceptive Advisors LLC bought a new stake in Revance Therapeutics in the 4th quarter valued at about $14,300,000. Institutional investors and hedge funds own 95.01% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Revance Therapeutics (RVNC) Stock Rating Reaffirmed by Guggenheim” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/23/revance-therapeutics-rvnc-stock-rating-reaffirmed-by-guggenheim.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.